Access by approval
The private entrance.
Access to AimwellBio is gated. This is the credentialed entry point for health professionals, researchers, biopharma and healthcare investors. We verify the person once. Observer access is free after approval, and the paid intelligence ladder opens from there.
- Reviewed on fit, not paid for
- A person reviews every submission
- 48-hour team response

The application
Tell us who you are.
- 1Application
- 2Review
- 3Access
Approval is reviewed on fit, not paid for. Not every organization is accepted.
Observer credentialing: include an NPI number, state license, institutional email, or peer-reviewed publication in the Additional Context field. Verification turnaround is 48 hours.
Application submitted
Your access request has been received. You’ll receive a confirmation email shortly.
- Within 24 hours: our team reviews your application and credentials. You may receive a follow-up email with questions.
- 3–5 business days: final access decision. Approved organizations receive onboarding within 2–4 weeks.
- On access: your intelligence infrastructure is configured to your organization. Onboarding call scheduled within 48 hours.
Questions? corporate@aimwellbio.com
Redirecting you to confirmation…
Enterprise deployment path
Designed for teams, scoped through review.
Enterprise access is not sold as a checkout button. It is scoped around the team, the signal category, the governance standard and the decision workflow. The path is request-based and moves at the pace of your review.
- Strategic reviewWe map the decisions at stake, the stakeholders involved, and where unverified AI-generated science is entering your stack.
- Source and use-case mappingWe align the signal categories you rely on with the specific use cases your team needs covered.
- Pilot workspaceA scoped workspace lets your team run the validation layer against real decisions before any broader rollout.
- Team access and governanceAccess expands to the wider team under the governance standard your organization requires.
- Reporting and expansionDecision-grade reporting feeds the next horizon of coverage, scoped through the same review.
Shield · in activation
What Shield provides when approved.
Shield is request-based while dossier and risk-room workflows are activated. When approved, the Shield layer organizes verified intelligence into the artifacts a decision team actually reviews. Access is scoped through review, not delivered on submission.
- Dossier-style risk packagingVerified findings assembled into a structured dossier for the decision in front of you.
- Regulatory movement reviewA read on the regulatory shifts that touch your signal category, traced to source.
- Confidence historyHow a verdict has held or shifted over time, kept as institutional memory.
- Escalation summaryA concise brief of what crossed the threshold and why it warrants attention.
- Decision memo exportAn export your team can carry into the room where the decision is made.
- Team review pathA shared path for the team to review, annotate and align before acting.
AimwellBio provides analytical and informational outputs to support organizational decision-making. It does not constitute medical advice, regulatory guidance, investment recommendations, or legal counsel. All intelligence outputs should be reviewed by qualified professionals before action is taken. AimwellBio is not a registered investment advisor, medical device, or regulatory authority.